Teva to shutter Montreal plant, cut 340 jobs; Baxter boosts earnings, raises outlook;

  @FiercePharma: Now that Brilinta's approved, AZ has to sell it. Story | Follow @FiercePharma

> Teva Pharmaceutical plans to shut down a Montreal plant acquired as part of its Ratiopharm buyout, having failed to find a buyer for the facility; the move will put 340 employees out of work. Report

> Baxter International reported higher-than-expected quarterly earnings, led by strong sales at its bioscience units, and raised its outlook for the full year. Report

> Prescriptions for Abbott Laboratories' Niaspan cholestserol drug fell 5% 6 weeks after a study that said the medicine failed to prevent heart attacks. Article

> Teva Pharmaceutical Industries said it settled patent litigation related to its generic versions of the Novartis blood-pressure drug Lotrel. News

> Express Scripts' takeover of Medco Health Solutions may fuel acquisitions of specialty pharmacy benefit managers by rivals seeking to gain enough size to negotiate lower prices with drugmakers. Report

> An FDA advisory panel backed an additional use of Johnson & Johnson's top-selling drug Remicade in pediatric patients, but said more data is needed about a rare cancer found in some young people treated with Remicade and similar drugs. Piece

> Danish drugmaker Lundbeck expects annual royalties from Japanese sales of its antidepressant Lexapro to peak in 6 or 7 years at above 500 million Danish crowns ($95.2 million). Item

> Shares of AmerisourceBergen fell 5% to $39.78 on worries that the company's lucrative contract with Medco Health Solutions could be in jeopardy now that it is being acquired by Express Scripts. News

> The FDA declared three pseudoephedrine-based medicines used to treat colds and allergies as controlled drugs. Report

> All strategic suppliers to Johnson & Johnson will need at least two publicly-reported sustainability goals under a new initiative by the healthcare giant. Report

Biotech News

@FierceBiotech: Roche could get groove back with potential early approvals of cancer drugs. Article | Follow @FierceBiotech

@JohnCFierce: The semagacestat Alzheimer's drug story demos again how little we know about consequences of messing with believed triggers. Item | Follow @JohnCFierce

 @RyanMFierce: Translational research is very difficult. Forbes lists the ways. Article | Follow @RyanMFierce

 @MaureenFierce: Experiments that insert human genes, cells into animals need rules to ensure they don't create 'monsters.' Article | Follow @MaureenFierce

> Bristol-Myers snapping up Amira Pharma for $325M. More

> Pfizer commits $100M to Mission Bay project. Story

And Finally... Lloyds pharmacy will open a pilot "health village" in a London retail center as part of its plan to become an all-round healthcare provider. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.